New heart pump takes on ECMO in High-Stakes stenting trial
NCT ID NCT06373120
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new temporary heart pump called CorVad against the standard ECMO machine in 262 high-risk patients who need complex heart stenting. The goal is to see which device better keeps the heart stable during the procedure and reduces complications like death, stroke, or kidney injury. Participants have severe coronary artery disease and weak hearts, making them too risky for bypass surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CorVad microaxial flow pump (a temporary heart assist device)
- What this could lead to
- If it works, this could show that a smaller, less invasive heart pump is safer and more effective than ECMO for supporting high-risk patients during complex stenting procedures.
- What could go wrong
- This is a relatively early randomized trial (262 patients) comparing two devices, so results may not apply to all patients. Both devices carry risks like bleeding, stroke, or kidney injury.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLEX CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ling Tao
Xi'an, Shannxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wrist access showdown: could a new approach reduce artery blockage after heart surgery?
- New heart pump device tested in High-Risk angioplasty patients
- Heart procedure complications linked to higher death risk in major new study
- New study aims to improve heart procedure outcomes for minority patients